Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P04637: Variant p.Gly325Val

Cellular tumor antigen p53
Gene: TP53
Feedback?
Variant information Variant position: help 325 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Glycine (G) to Valine (V) at position 325 (G325V, p.Gly325Val). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to medium size and hydrophobic (V) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In LFS; germline mutation. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 325 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 393 The length of the canonical sequence.
Location on the sequence: help KRALPNNTSSSPQPKKKPLD G EYFTLQIRGRERFEMFRELN The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         KRALPNNTS-SSPQPK--KKPL----DGEYFTLQIRGRERFEMFRELN

                              KRALPPSTS-SSPPQK--KKPL----DGEYFTLQIRGRERY

Rhesus macaque                KRALPNNTS-SSPQPK--KKPL----DGEYFTLQIRGRERF

Mouse                         KRALPTCTS-ASPPQK--KKPL----DGEYFTLKIRGRKRF

Rat                           KRALPTSTS-SSPQQK--KKPL----DGEYFTLKIRGRERF

Pig                           KRALPTSTS-SSPVQK--KKPL----DGEYFTLQIRGRERF

Bovine                        KRALPTNTS-SSPQPK--KKPL----DGEYFTLQIRGFKRY

Rabbit                        KRALPTTTTDSSPQTK--KKPL----DGEYFILKIRGRERF

Sheep                         KRALPSSTS-SSPQQK--KKPL----DGEYFTLQIRGRKRF

Cat                           KRALPPSTS-STPPQK--KKPL----DGEYFTLQIRGRERF

Chicken                       KRAMSPPTE-APEPPK--KRVL--NPDNEIFYLQVRGRRRY

Xenopus laevis                ELAHPPSSE--PPLPK--KRLVVVDDDEEIFTLRIKGRSRY

Zebrafish                     RSLVKESSS-ATLRPEGSKKAKGSSSDEEIFTLQVRGRERY

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 393 Cellular tumor antigen p53
Region 100 – 370 Interaction with HIPK1
Region 282 – 325 Disordered
Region 300 – 393 Interaction with CARM1
Region 319 – 360 Interaction with HIPK2
Region 325 – 356 Oligomerization
Modified residue 305 – 305 N6-acetyllysine
Modified residue 315 – 315 Phosphoserine; by AURKA, CDK1 and CDK2
Modified residue 321 – 321 N6-acetyllysine
Modified residue 333 – 333 Omega-N-methylarginine; by PRMT5
Modified residue 335 – 335 Symmetric dimethylarginine; by PRMT5
Modified residue 337 – 337 Symmetric dimethylarginine; by PRMT5
Mutagenesis 319 – 319 K -> A. Loss of nuclear localization; when associated with A-320 and A-321.
Mutagenesis 320 – 320 K -> A. Loss of nuclear localization; when associated with A-319 and A-321.
Mutagenesis 321 – 321 K -> A. Loss of nuclear localization; when associated with A-319 and A-320.



Literature citations
Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms.
Malkin D.; Jolly K.W.; Barbier N.; Look A.T.; Friend S.H.; Gebhardt M.C.; Andersen T.I.; Boerresen A.-L.; Li F.P.; Garber J.; Strong L.C.;
N. Engl. J. Med. 326:1309-1315(1992)
Cited for: VARIANTS LFS HIS-273 AND VAL-325;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.